We deliver you hope and ability to escape of hepatitis C and leave this life experience behind you.

*
Ledipasvir, sofosbuvir, and GS-331007 are not inhibitors or inducers of CYP or UGT1A1 enzymes.
The US Food and Drug Administration (FDA) has approved the first-in-kind nucleotide analog inhibitor sofosbuvir ( Sovaldi . Gilead Sciences, Inc) for the treatment of adults with chronic hepatitis C virus (HCV) infection, a widely anticipated move that is expected to dramatically improve outcomes for many patients.
In Part 1, as proof of concept, 10 people with absent to moderate liver fibrosis (stage F0-F2) were treated with 400 mg once-daily oral sofosbuvir plus weight-based ribavirin dosed at 1000 mg/day if they weighed <75 kg or 1200 mg/day if > 75 kg, divided into 2 daily doses. In Part 2, 50 people with all stages of liver disease were randomly assigned (1:1) to receive the same dose of sofosbuvir plus either weight-based ribavirin or a lower fixed dose of 600 mg/day regardless of weight, in an effort to reduce the risk of anemia. Everyone was treated for 24 weeks.
maz68.ru/index.php/forum?func=view&catid=3&id=9646
The drug, called ABT-450, is pending approval by the U.S. Food and Drug Administration and should be commercially available in late 2014 or early 2015. It will be manufactured by AbbVie, which also funded the German study of the drug. The cost of the ABT-450 is expected to be fairly high, making critics wonder if patients who cannot afford the drug would decline its uses in their treatment. A similar drug for hepatitis C called Sovaldi comes with a $90,000 price tag for its three-month course of treatment. While some insurance companies are covering Sovaldi, others are not. Researchers hope that their new drug will be covered by all insurance companies because it offers a cure for the virus, negating long-term care costs for those who develop cirrhosis or liver cancer. Also in question is the ease of the drug’s use, which requires some pills to be taken once a day, while some are taken twice a day, which will necessitate careful planning and the development of rigid habits in patients taking the drug.
The Global Sofosbuvir Industry report gives a comprehensive account of the Global Sofosbuvir market. Details such as the size, key players, segmentation, SWOT analysis, most influential trends, and business environment of the market are mentioned in this report. Furthermore, this report features tables and figures that render a clear perspective of the Sofosbuvir market. The report features an up-to-date data on key companies' product details, revenue figures, and sales. Furthermore, the details also gives the Global Sofosbuvir market revenue and its forecasts. The business model strategies of the key firms in the Sofosbuvir market are also included. Key strengths, weaknesses, and threats shaping the leading players in the market have also been included in this research report.
Lawmakers want to know why VA shouldn't be receiving a portion of the sales if one of its employees or its resources were used in Sovaldi's discovery. The agency has a longstanding interest in a cure for hepatitis C, with more than 300,000 veterans -- many of them Vietnam vets -- suffering from it.
Is there any funding or copay coupon available in CANADA? We have govt medical care here but it does not cover Sovaldi.
India's generics pharmaceutical industry got a major recognition and boost recently when Gilead Sciences decided to licence manufacturing of its best selling Hepatits C drug Sovladi to seven Indian companies. Sovaldi, approved only last December, is already on track to be a blockbuster drug with sales expected to cross $11 billion in its first year in the market.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Dec. 6, 2013-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Sovaldi™ (sofosbuvir) 400 mg tablets, a once-daily oral nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen.
From 1 March 2016, people with genotype 2 will be offered a course of Sovaldi ® and Ibavyr ® direct acting antiviral pills. This option offers a 93% success rate (chance of cure).